Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2754865 | 0.91 | PRKCA (0.36) | ACHECYP4F2CYP4A11TSHRPRKCA | |
| SCHEMBL13785298 | 0.88 | ALDH1A1 (0.36) | ACHECYP4F2CYP4A11TSHRPRKCA | |
| SCHEMBL23344902 | 0.88 | MEN1 (0.42) | CYP4F2CYP4A11TSHRPRKCAALDH1A1 | |
| SCHEMBL21574923 | 0.88 | ACHE (0.34) | ACHECYP4F2CYP4A11TSHRPRKCA | |
| SCHEMBL12238113 | 0.88 | CYP4F2 (0.37) | ACHECYP4F2CYP4A11TSHRPRKCA | |
| SCHEMBL25697373 | 0.87 | CYP4F2 (0.43) | ACHECYP4F2CYP4A11TSHRPRKCA | |
| SCHEMBL10017774 | 0.86 | TSHR (0.43) | ACHECYP4F2CYP4A11TSHRPRKCA | |
| SCHEMBL20244543 | 0.85 | ACHE (0.33) | ACHECYP4F2CYP4A11TSHRGAA | |
| SCHEMBL18373345 | 0.84 | CYP4F2 (0.33) | ACHECYP4F2CYP4A11TSHRCHRM2 | |
| SCHEMBL28731535 | 0.84 | TSHR (0.38) | ACHECYP4F2CYP4A11TSHRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481976-B1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8026273-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100098761-A1 | Polymer Compositions For Biomedical And Material Applications | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL | 2010-04-22 | — | — | US | disclosed |
| US-7683094-B2 | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-7402605-B2 | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| EP-1481976-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124577-A1 | 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | PTGER2, PTGIS, HPGDS | ACHE 1166/4885CYP4F2 489/4885CYP4A11 215/4885 |
| US-20090042885-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | ACHE 926/4885CYP4F2 712/4885CYP4A11 225/4885 |
| US-20100113388-A1 | 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT | PTGER2, PTGIS, HPGDS | ACHE 926/4885CYP4F2 712/4885CYP4A11 225/4885 |
| US-20100098761-A1 | Polymer Compositions For Biomedical And Material Applications | ILK, ECPAS, PTH1R | ACHE 1525/4885CYP4F2 4447/4885CYP4A11 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.